Document Detail

Survival and cycle-progression delay of human lymphoma cells in vitro exposed to VP-16-213.
MedLine Citation:
PMID:  1016966     Owner:  NLM     Status:  MEDLINE    
The lethal and kinetic effects of VP-16-213 were analyzed in a human lymphoid cell line (T1 cells) in vitro. When asynchronous T1 cells were exposed to increasing concentrations of VP-16-213 for 1 hour, an exponential survival curve with a Do (mean lethal dose equal to the concentration required to reduce survival by 63% on the exponential part of the survival curve) of 3 mug/ml was obtained. Increasing exposure time also reduced survival exponentially. Synchronized cells showed age-dependent sensitivity to VP-16-213 with the greatest lethal damage experienced by cells treated in S and G2 phase. The major kinetic response of the T1 cells to VP-16-213 was a delay in G2 phase, the extent and duration of which was a function of drug concentration, exposure time, and cell cycle stage of drug addition; thus, cells in S phase were most effectively blocked in the subsequent G2 phase. Continuous treatment with concentrations of VP-16-213 (greater than 0.5 mug/ml for greater than 3 hours) caused a retardation of S-phase transit with prompt recovery after drug release. Treatment with 10.0 mug/ml for greater than 3 hours resulted in a "frozen state" of the whole life cycle, inducing only minor compartment changes. DNA synthesis was inhibited in the majority of cells with an S-phase DNA content. There was no correlation between the extent of perturbation and lethal effects after treatment with VP-16-213.
B Drewinko; B Barlogie
Related Documents :
22465356 - Cell volume changes during apoptosis monitored in real time using digital holographic m...
20883816 - Iqgap1 translocates to the nucleus in early s-phase and contributes to cell cycle progr...
10398746 - Stimulation of the multiplication of micrococcus luteus by an autocrine growth factor.
3225736 - Quantitative cytological analysis of functional changes in adrenomedullary chromaffin c...
8435066 - Comparison of the levels of inositol metabolites in transformed haemopoietic cells and ...
3607006 - Role for an episulfonium ion in s-(2-chloroethyl)-dl-cysteine-induced cytotoxicity and ...
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Cancer treatment reports     Volume:  60     ISSN:  0361-5960     ISO Abbreviation:  Cancer Treat Rep     Publication Date:  1976 Sep 
Date Detail:
Created Date:  1977-04-30     Completed Date:  1977-04-30     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7607107     Medline TA:  Cancer Treat Rep     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1295-1306     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cell Division / drug effects*
Cell Line
Cell Survival / drug effects*
Dose-Response Relationship, Drug
Etoposide / pharmacology*
Lymphoma* / pathology
Neoplasms, Experimental* / pathology
Podophyllotoxin / analogs & derivatives*
Reg. No./Substance:
33419-42-0/Etoposide; 518-28-5/Podophyllotoxin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Studies of the effects of cyclophosphamide, vincristine, and prednisone on some hepatic oxidations a...
Next Document:  Studies with 2,5-piperazinedione, 3,6-bis(5-chloro-2-piperidyl)-,dihydrochloride. II. Effects on mac...